Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

S. Kusumoto, L. Arcaini, X. Hong, J. Jin, W.S. Kim, Y.L. Kwong, M.G. Peters, Y. Tanaka, A.D. Zelenetz, H. Kuriki, G. Fingerle-Rowson, T. Nielsen, E. Ueda, H. Piper-Lepoutre, G. Sellam, K. Tobinai

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)137-146
Number of pages10
Issue number2
Publication statusPublished - 2019

Cite this